银丹心脑通软胶囊通过CREB/BDNF与CREB/VEGFA通路促进脑卒中后恢复
本研究探讨银丹心脑通软胶囊(YD)对缺血性脑卒中后恢复的作用及机制。采用MCAO/R与OGD/R模型,结合行为学、病理与RNA-seq分析,发现YD减轻脑萎缩与神经功能缺损,上调突触可塑性及血管新生标志物,机制涉及CREB/BDNF与CREB/VEGFA通路,并筛选出丹酚酸B和烟花苷为主要活性成分。
要点
- YD减轻缺血再灌注后脑萎缩体积、神经功能缺损及认知运动障碍。
- YD通过CREB/BDNF促进突触可塑性、CREB/VEGFA促进血管新生。
- 丹酚酸B与烟花苷为高CREB亲和力的主要活性成分。
核心结论
- YD通过CREB/BDNF介导的突触可塑性和CREB/VEGFA介导的血管新生促进缺血性脑卒中后恢复。
研究设计与样本
- 采用MCAO/R和OGD/R模型,结合TTC、H&E、Nissl、Golgi染色、TEM、行为学测试、RNA-seq、网络药理学、分子对接及2D单层细胞和3D神经血管单元球体验证。
主要发现
- YD显著减轻卒中后脑萎缩体积、神经功能缺损评分、认知/运动障碍及病理结构和海马突触超微结构损伤。
- 535个差异表达基因分析显示CREB信号通路(关键靶点CREB、BDNF、VEGFA)为核心机制。
- 突触可塑性标志物synaptophysin和血管新生标志物CD31在脑组织及3D NVU球体中分别经CREB/BDNF和CREB/VEGFA通路上调。
- CREB抑制剂666-15共处理减弱YD对CREB磷酸化的影响。
- 丹酚酸B(来自丹参)和烟花苷(来自银杏叶)被鉴定并验证为高CREB亲和力的主要活性成分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ischemic stroke is a leading cause of disability and cognitive impairment. Yindan Xinnaotong Soft Capsule (YD), a traditional Chinese patent medicine, is clinically utilized for cardio-cerebrovascular diseases, yet its potential roles in post-stroke recovery remains unclear. PURPOSE: To elucidate the protective effects and underlying mechanisms of YD on ischemic post-stroke recovery. METHODS: Middle cerebral artery occlusion/reperfusion (MCAO/R) and oxygen-glucose deprivation/reperfusion (OGD/R) models were utilized to investigate the effects of YD on post-stroke recovery. Cerebral atrophy (TTC staining), histopathology (H&E, Nissl, and Golgi staining), synaptic ultrastructure (transmission electron microscopy, TEM), and behavioral tests were assessed. RNA-seq and network pharmacology analysis were utilized to reveal the underlying mechanisms, and verified in brain tissues, 2D monolayer cell, and 3D neurovascular unit (NVU) spheroids. Molecular docking was performed to screen the potential active ingredients and verified by immunofluorescence and cellular thermal shift assay. RESULTS: YD significantly alleviated post-stroke brain atrophy volume, neurological deficit score, cognitive/motor deficit, and pathological structure and hippocampal synaptic ultrastructure damage. A total of 535 differentially expressed genes analysis revealed that CREB signaling with the key targets of CREB, BDNF, and VEGFA was the central mechanism. The synaptic plasticity marker of synaptophysin and angiogenesis marker of CD31 were upregulated in brain tissues and 3D NVU spheroids mediated by CREB/BDNF and CREB/VEGFA pathway, respectively. Co-treatment with the CREB inhibitor 666-15 attenuated YD's effects on CREB phosphorylation. Salvianolic acid B (from Salvia miltiorrhiza Bunge) and Kaempferol-3-O-rutinoside (from Ginkgo biloba leaf) were identified and validated as primary active ingredients with high CREB affinity. CONCLUSION: Our study demonstrated that YD promoted post-ischemic stroke recovery by promoting CREB/BDNF-mediated synaptic plasticity and CREB/VEGFA-mediated angiogenesis, highlighting its therapeutic potential for treating long-term cerebral ischemia injury.
引用
- Cheng C, Liu H, Guan G, et al. Yindan Xinnaotong Soft Capsule improves post-ischemic stroke recovery by regulating CREB/BDNF-mediated synaptic plasticity and CREB/VEGFA-mediated angiogenesis. Phytomedicine. 2025. PMID: 40819643. doi:10.1016/j.phymed.2025.157155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。